Analysis

Nigeria’s HIV ‘breakthrough’: separating truth from hope

Nigeria’s HIV ‘breakthrough’: separating truth from hope

A peptide to prevent pre-diabetes

A peptide to prevent pre-diabetes

Pharma Technology Focus – Issue 56

Pharma Technology Focus – Issue 56

Why the UK NHS needs clinical research

Why the UK NHS needs clinical research

After the cure: addressing side effects in childhood cancer patients

After the cure: addressing side effects in childhood cancer patients

Pharma Technology Focus – Issue 54

Pharma Technology Focus – Issue 54

Debating the value of targeted lung cancer treatments

Debating the value of targeted lung cancer treatments

Genomic array could unlock war against diseases in Africa

Genomic array could unlock war against diseases in Africa

Ketamine: taking aim at depression

Ketamine: taking aim at depression

Antibiotic resistance: the race for the prize

Antibiotic resistance: the race for the prize

Developing new drugs for Tourette syndrome

Developing new drugs for Tourette syndrome

Plague, Flu and Zika: could 2017 bring vaccines for all three?

Plague, Flu and Zika: could 2017 bring vaccines for all three?

Pharma Technology Focus – Issue 51

Pharma Technology Focus – Issue 51

Is the stage set for global drug price regulation?

Is the stage set for global drug price regulation?

How rebuilding entire immune systems could be the key to curing MS

How rebuilding entire immune systems could be the key to curing MS

Pharma Technology Focus – Issue 50

Pharma Technology Focus – Issue 50

Xilonix: new anti-tumour cancer drug is on the fast-track

Xilonix: new anti-tumour cancer drug is on the fast-track

ChemoFilter: getting the drugs back out

ChemoFilter: getting the drugs back out

Psilocybin vs. depression: London study overcomes obstacles to show encouraging results

Psilocybin vs. depression: London study overcomes obstacles to show encouraging results

Watching the clock: should day and night influence our drug regimens?

Watching the clock: should day and night influence our drug regimens?

July's top stories: Cancer Drugs Fund implemented in UK, Nichi-Iko acquired Sagent Pharmaceuticals

July's top stories: Cancer Drugs Fund implemented in UK, Nichi-Iko acquired Sagent Pharmaceuticals
cachename:Featurescachekey:rd-137342983_-144940029_rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_1970823743